This company has been marked as potentially delisted and may not be actively trading. NASDAQ:ONCT Oncternal Therapeutics (ONCT) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisHeadlinesInsider TradesTrendsBuy This Stock About Oncternal Therapeutics Stock (NASDAQ:ONCT) 30 days 90 days 365 days Advanced Chart Get Oncternal Therapeutics alerts:Sign Up Key Stats Today's Range$0.53▼$0.5350-Day Range$0.53▼$0.5352-Week Range$0.53▼$7.17VolumeN/AAverage Volume99,758 shsMarket Capitalization$1.56 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial. It is also developing ONCT-808, a chimeric antigen receptor T-cells (CAR-T), which is in Phase 1/2 clinical trial for the treatment of hematologic malignancies and solid tumors, as well as targets ROR1; and ONCT-534, a dual-action androgen receptor inhibitor product candidate in preclinical development for the treatment of castration-resistant prostate and other androgen receptor-driven cancers. The company has license agreements with the Regents of the University of California; Georgetown University; The University of Texas MD Anderson Cancer Center; Shanghai Pharmaceutical (USA) Inc.; and University of Tennessee Research Foundation. Oncternal Therapeutics, Inc. is headquartered in San Diego, California. Read More Receive ONCT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Oncternal Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ONCT Stock News HeadlinesOncternal Therapeutics Announces the Sale of Select Development Programs and the Wind-Down of its OperationsJuly 1, 2025 | globenewswire.comChronic Lymphocytic Leukemia Pipeline Appears Robust With 55+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsightJune 17, 2025 | theglobeandmail.comForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW kind of AI stock.September 16 at 2:00 AM | Chaikin Analytics (Ad)Marginal Zone Lymphoma Pipeline Appears Robust With 50+ Pharma Companies Actively Working in the Therapeutics Segment | DelveInsightMay 21, 2025 | theglobeandmail.comOncternal Therapeutics Announces Intent to Voluntarily Delist from Nasdaq and Deregister with the SECMarch 7, 2025 | globenewswire.comOncternal Therapeutics (NASDAQ:ONCT) Stock, Short Interest ReportNovember 26, 2024 | benzinga.comOncternal Therapeutics Reports Q3 2024 EarningsNovember 21, 2024 | markets.businessinsider.comOncternal announces workforce reduction, executive changesNovember 17, 2024 | investing.comSee More Headlines ONCT Stock Analysis - Frequently Asked Questions How were Oncternal Therapeutics' earnings last quarter? Oncternal Therapeutics, Inc. (NASDAQ:ONCT) issued its quarterly earnings results on Thursday, August, 8th. The company reported ($2.89) earnings per share for the quarter, topping analysts' consensus estimates of ($3.03) by $0.14. The firm earned $0.80 million during the quarter, compared to analysts' expectations of $0.24 million. Oncternal Therapeutics had a negative net margin of 1,599.95% and a negative trailing twelve-month return on equity of 177.58%. Read the conference call transcript. When did Oncternal Therapeutics' stock split? Oncternal Therapeutics's stock reverse split on Monday, January 8th 2024.The 1-20 reverse split was announced on Monday, January 8th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Monday, January 8th 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What other stocks do shareholders of Oncternal Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Oncternal Therapeutics investors own include NIO (NIO), Walt Disney (DIS), Tesla (TSLA), Plug Power (PLUG), Meta Platforms (META) and Moderna (MRNA). Company Calendar Last Earnings8/08/2024Today9/16/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ONCT CIK1260990 Webwww.oncternal.com Phone(858) 434-1113Fax901-844-8075Employees30Year FoundedN/AProfitability EPS (Trailing Twelve Months)($11.69) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$39.48 million Net Margins-1,599.95% Pretax Margin-1,599.95% Return on Equity-177.58% Return on Assets-131.30% Debt Debt-to-Equity RatioN/A Current Ratio2.39 Quick Ratio2.39 Sales & Book Value Annual Sales$790 thousand Price / Sales1.97 Cash FlowN/A Price / Cash FlowN/A Book Value$10.19 per share Price / Book0.05Miscellaneous Outstanding Shares2,960,000Free Float2,628,000Market Cap$1.56 million OptionableNo Data Beta1.18 Social Links Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:ONCT) was last updated on 9/16/2025 by MarketBeat.com Staff From Our PartnersSean Hannity: Help Protect Your RetirementThis Guide to retirement protection has helped thousands protect over $3 billion dollars in retirement savings...Goldco Precious Metals | SponsoredWhat a Former CIA Agent Knows About the Coming Collapse This isn’t just another gold investing book—it’s a survival playbook written by a former CIA officer trained...Advantage Gold | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredWhy More Investors Are Using Family Trusts to Protect Their WealthFor many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensur...SmartAsset | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredTrump’s Plan May Undo 1933’s Biggest Financial InjusticeTrump's Reset Can Give Birth To America's Greatest Era Yet A 90-Year cycle may end soon, creating real weal...American Hartford Gold | SponsoredGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | SponsoredCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oncternal Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oncternal Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.